Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
Sight Sciences’ $240 Million Initial Public Offering
Theravance Biopharma’s $100.5 Million Shares Offering
Davis Polk advised the underwriters in the offering. Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq...